Home Daily Intelligence Tracker
    • Plans Blog Contact
    Adial Pharmaceuticals Inc logo
    ADIL

    Adial Pharmaceuticals Inc

    MaveScore 29 Low model confidence
    Last Price US$2.78 As of Jul 10, 2026
    Market Cap US$4.2m Company size context
    7D Performance -4.14% Past 7 days
    1Y Performance N/A Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    14/16

    2 missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 29 Low confidence

    Stored data quality

    Freshness and coverage checks

    14/16 Current stored snapshot

    Quality

    8/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    0/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    5/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    15/15 Strong

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    1/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Adial Pharmaceuticals Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcoho Read More

    Adial Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Adial Pharmaceuticals Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 11, 2026

    Quarterly result summary

    Net loss was -$2M (from $2.2M). Cash was $4.6M.

    Net loss -$2M from $2.2M
    Cash $4.6M reported

    What changed

    • Net loss was -$2M (from $2.2M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing CURRENT REPORT May 11, 2026 SEC filing QUARTERLY REPORT May 08, 2026 SEC filing CURRENT REPORT Mar 06, 2026 Earnings release PRESS RELEASE ISSUED BY ADIAL PHARMACEUTICALS, INC., MARCH 6, 2026 Mar 06, 2026 SEC filing ANNUAL REPORT Mar 05, 2026 Earnings release PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON NOVEMBER 14, 2025 Nov 14, 2025 SEC filing CURRENT REPORT Nov 14, 2025 SEC filing QUARTERLY REPORT Nov 13, 2025 SEC filing CURRENT REPORT Aug 14, 2025 Earnings release PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON AUGUST 14, 2025 Aug 14, 2025 SEC filing QUARTERLY REPORT Aug 13, 2025

    Recent News



    EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For ...
    Yesterday
    Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of ...
    Yesterday
    Will Adil Rashid and Akeal Hosein hold the key?
    2 days ago

    Earnings Per Share

    Score 1.00/5
    Adial Pharmaceuticals Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 0.08/5
    Adial Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Adial Pharma... ADIL US$4.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Adial Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Adial Pharma... ADIL US$4.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.07/5
    Adial Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Adial Pharma... ADIL US$4.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Adial Pharmaceuticals Inc logo

    Adial Pharmaceuticals Inc

    US$2.78

    US$4.2m

    -4.14%

    N/A